Download as pdf or txt
Download as pdf or txt
You are on page 1of 9

Supplemental material to this article can be found at:

http://molpharm.aspetjournals.org/content/suppl/2015/10/05/mol.115.100503.DC1
1521-0111/88/6/9931001$25.00 http://dx.doi.org/10.1124/mol.115.100503
MOLECULAR PHARMACOLOGY Mol Pharmacol 88:9931001, December 2015
Copyright 2015 by The American Society for Pharmacology and Experimental Therapeutics

Molecular Basis for Differential Sensitivity of a-Conotoxin RegIIA


at Rat and Human Neuronal Nicotinic Acetylcholine Receptors s

Shiva N. Kompella,1,2 Hartmut Cuny,2 Andrew Hung, and David J. Adams


Health Innovations Research Institute (S.N.K., H.C., A.H., D.J.A.) and School of Applied Sciences (A.H.), RMIT University,
Melbourne, Victoria, Australia
Received June 22, 2015; accepted October 1, 2015

ABSTRACT

Downloaded from molpharm.aspetjournals.org at ASPET Journals on August 30, 2017


a-Conotoxins, as nicotinic acetylcholine receptor (nAChR) antag- voltage clamp recordings used to investigate the effects of the
onists, are powerful tools for dissecting biologic processes and peptides on nAChR activity. RegIIA potently inhibited currents
guiding drug development. The a3b2 and a3b4 nAChR subtypes evoked by acetylcholine (ACh) at rat a3b2 (IC50 5 10.7 nM),
are expressed in the central and peripheral nervous systems and whereas a 70-fold lower potency was observed at human a3b2
play a critical role in various pathophysiological conditions ranging nAChR (IC50 5 704.1 nM). Conversely, there were no species-
from nicotine addiction to the development and progression of specific differences in sensitivity to RegIIA at the a3b4 nAChR.
lung cancer. Here we used the a4/7-conotoxin RegIIA, a disulfide- Receptor mutagenesis and molecular dynamics studies revealed
bonded peptide from the venom of Conus regius, and its analog that this difference can be attributed primarily to a single amino
[N11A,N12A]RegIIA to probe the specific pharmacological prop- acid change: Glu198 on the rat a3 subunit corresponding to a
erties of rat and human nAChR subtypes. nAChR subtypes were proline on the human subunit. These findings reveal a novel
heterologously expressed in Xenopus oocytes and two-electrode species- and subunit-specific receptor-antagonist interaction.

Introduction the a3b2 nAChR subtype is expressed in specific areas of the


central and peripheral nervous systems, including the medial
Neuronal nicotinic acetylcholine receptors (nAChR) are habenula, cerebellum, spinal cord, retina, and autonomic ganglia
pentameric transmembrane proteins forming ligand-gated
(Millar and Gotti, 2009; Hurst et al., 2013). However, owing to a
ion channels that are sensitive to nicotine and endogenously
lack of subtype-selective tools, our knowledge of the exact roles
activated by acetylcholine (ACh). Most neuronal nAChR
of individual nAChR subtypes in pathophysiological states is
subtypes form heteropentamers of a26 and b24 subunits
limited. This in turn severely limits the ability to fully exploit
combined in different stoichiometries (Millar and Gotti, 2009).
nAChR pharmacology for potential pharmaceutical applica-
Neuronal nAChRs are important components of synaptic
tions, evidenced by a number of drugs failing in late-state
transmission and are expressed pre- and postsynaptically in
clinical trials (Decker et al., 2008).
the peripheral nervous system, and in cholinergic neurons
a-Conotoxins are short disulfide-bonded peptides (1220 amino
throughout the brain (Jensen et al., 2005). They regulate the
acid residues) isolated from the venom of marine snails of the
release of several neurotransmitters and are functionally
Conus genus. a-Conotoxins are classified as selective antagonists
involved in various cognitive roles, such as learning, memory,
of muscle and neuronal nAChRs and are promising pharmaco-
and motor control (Jensen et al., 2005). Not surprisingly,
logical probes and potential therapeutics (Olivera et al., 2008;
neuronal nAChR activity is also involved in a wide range of
Muttenthaler et al., 2011; Lebbe et al., 2014). a4/7-Conotoxin
disease states. For example, the a3b4 nAChR is implicated in
RegIIA, isolated from the venom of Conus regius, has previously
tobacco addiction, drug abuse, and lung cancer (Jensen et al.,
been characterized as a potent inhibitor of rat a3b2, a3b4,
2005; Hurst et al., 2013), making this particular nAChR
and human a7 nAChRs at nanomolar concentrations (Franco
subtype an interesting target for novel therapeutics. Similarly
et al., 2012). Furthermore, a recent study using alanine-scanning
mutagenesis identified a novel [N11A,N12A]RegIIA analog that
This work was supported by the Australian Research Council (ARC)
[Discovery Project Grant DP1093115]. D.J.A. is an ARC Australian Pro- selectively targets the rat a3b4 nAChR subtype (Kompella et al.,
fessorial Fellow. Computational resources were provided by the Victorian Life 2015). Recent literature suggests a-conotoxins not only have a
Science Computation Initiative (VLSCI) and V3 Alliance.
1
Current affiliation: Faculty of Pharmacy, University of Sydney, Sydney,
characteristic activity profile for different nAChR subtypes, but
New South Wales 2006, Australia. E-mail: shiva.kompella@sydney.edu.au also exhibit selective activity on subtypes of different species
2
Contributed equally to this research. (Azam and McIntosh, 2012; Yu et al., 2013). Species differences
dx.doi.org/10.1124/mol.115.100503.
s This article has supplemental material available at molpharm.aspetjournals. could result in discrepancies during preclinical testing that guides
org. clinical trials and are therefore of pharmaceutical significance.

ABBREVIATIONS: ACh, acetylcholine; AChBP, acetylcholine binding protein; DGbind, binding free energy; (D)DGbind, relative binding free energy;
ECD, extracellular domain; IC50, half-maximal inhibitory concentration; MD, molecular dynamics; MM-PBSA, molecular mechanicsPoisson-
Boltzmann surface area; nAChR, nicotinic acetylcholine receptor.

993
994 Kompella et al.

Here, we report the novel species- and subunit-specific curves were fitted by unweighted nonlinear regression to the logistic
pharmacology exhibited by a-conotoxin RegIIA at a3b2 and equation
a3b4 nAChR subtypes. Using receptor mutagenesis and  
Ex 5 Emax XnH XnH 1 ICn50H (1)
molecular dynamic simulations, we identify the key inter-
actions involved in differential RegIIA activity at these where Ex is the response, X is the antagonist concentration, Emax is the
receptors. maximal response, nH is the Hill coefficient, and IC50 is the antagonist
concentration that gives 50% inhibition of the agonist response. All
electrophysiological data were pooled (n 5 48 for each data point) and
Materials and Methods represent arithmetic means 6 standard error of the fit. Curves were
fitted and statistics calculated using GraphPad Prism 6 (GraphPad
Peptide Synthesis. a-Conotoxins RegIIA and [N11A,N12A]
Software Inc., La Jolla, CA).
RegIIA were synthesized as described previously (Kompella et al.,
Homology Modeling. Homology models were generated using
2015) and obtained from Dr. Richard J. Clark, University of Queens-
Modeler9v6 (Sali and Blundell, 1993). Homology models of the ECD of
land, Australia.
rat and human (a3)2(b2)3, and rat (a3[Q198P])2(b2)3 bound to RegIIA
Protein Sequence Alignment. Protein sequences of rat and
were constructed using the coordinates of Aplysia californica acetyl-
human a3 (RefSeq accession numbers NP_434692 and NP_000734,
choline binding protein (AChBP) cocrystallized with a-conotoxin PnIA
respectively) and b2 nAChR subunits (RefSeq accession numbers
[A10L,D14K] [Protein Data Bank (PDB) accession code 2BR8; Data
NP_062170 and NP_000739, respectively) were aligned using CLC
Supplement File #1] (Celie et al., 2005) as a template. Homology
Viewer 7 software (CLC bio, Aarhus, Denmark). Residues were

Downloaded from molpharm.aspetjournals.org at ASPET Journals on August 30, 2017


models of the apo ECD of the respective receptors were constructed
numbered according to the sequences of the mature proteins.
on the basis of the crystallographic coordinates of Aplysia californica
Site-Directed Mutagenesis of a3 and b2 nAChR Subunits.
apo AChBP (PDB accession code 2BYN; Data Supplement File #2)
Plasmid DNAs encoding human a3, b2 and b4 nAChR subunits were
(Hansen et al., 2005).
obtained from OriGene Technologies Inc. (Rockville, MD) and the full-
length cDNAs were subcloned into the pT7TS Xenopus expression Molecular Dynamics Simulations. Each receptor complex was
vector (Addgene plasmid 17091). Rat a3, b2 and b4 nAChR cDNA placed in a separate cubic simulation box with edge length 100  100 
clones described previously (Franco et al., 2012) were also subcloned 100 and solvated with TIP3P water molecules. Na1 and Cl2 were
into pT7TS. Individual amino acids in the N-terminal extracellular added to neutralize charge and maintain an ionic concentration of
domain (ECD) that precedes transmembrane segment I of rat a3 and 150 mM. All simulations were performed using GROMACS version
b2 nAChRs were mutated to the corresponding human residues using 4.6.3 (Science for Life Laboratory, Stockholm, Sweden; Lindahl et al.,
the Geneart Site-Directed Mutagenesis System (Invitrogen, Carlsbad, 2001; Van Der Spoel et al., 2005) with the CHARMM27 force-field
CA). Rat a3 nAChR constructs generated were ra3[D97V], ra3[E187D], version 2.0 (with cmap) (Bjelkmar et al., 2010). The complexes were
ra3[Q198P], and a ra3[Q73G]1[V75A] double mutant. Owing to the energy-minimized using the steepest descent algorithm and an energy
close proximity of Q73 and V75, these residues were mutated with one gradient convergence criterion of 0.01 kcal/mol per angstrom. All
pair of mutagenesis primers. Rat b2 nAChR constructs generated molecular dynamics (MD) simulations were performed using constant
were rb2[D73E], rb2[D165E], and rb2[I181V]. The human a3 mutant particle number, pressure, and temperature (NPT) ensemble, with
ha3[P198Q] was also generated. All point mutations were confirmed temperature maintained at 300 K using the v-rescale temperature
by DNA sequencing (Australian Genome Research Facility, Melbourne, coupling algorithm (Bussi et al., 2007), and pressure maintained at
Australia). 1 bar using the Parrinello-Rahman pressure coupling algorithm
Electrophysiological Recordings in Xenopus Oocytes. RNA (Parrinello and Rahman, 1981). Time steps of 2 femtoseconds were
preparation, Xenopus laevis oocyte preparation, and expression of used to integrate all simulations. Ten independent simulations were
nAChR subunits in oocytes were performed as described previously performed for each complex using different random seeds to assign
(Hogg et al., 2003). Briefly, plasmids were linearized with appropriate initial particle velocities. Each simulation was performed for 20 nano-
restriction enzymes, and cRNA synthesized in vitro with the T7 seconds. Molecular graphics were produced using VMD version 1.9.2
mMessage mMachine Kit (Ambion, Foster City, CA). Oocytes were (http://www.ks.uiuc.edu/; Humphrey et al., 1996).
injected with 5 ng of cRNA, and then kept at 18C in sterile ND96 Molecular MechanicsPoisson-Boltzmann Surface-Area
buffer (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, and Calculations. The binding free energies (DGbind) of RegIIA to rat and
5 mM HEPES, at pH 7.4) supplemented with 50 mg/l gentamycin and human (a3)2(b2)3, and rat (a3[Q198P])2(b2)3, were calculated using the
100 mg/IU per milliliter penicillin/streptomycin for 25 days before molecular mechanicsPoisson-Boltzmann surface-area (MM-PBSA)
recording. method implemented in the GROMACS tools g_mmpbsa (Kumari
Membrane currents from Xenopus oocytes were recorded using a et al., 2014) and APBS (Dolinsky et al., 2004, 2007). The binding
single-channel two-electrode voltage clamp setup (virtual ground free energy is defined as DGbind 5 Gcomplex Gfree-protein Gfree-ligand.
circuit) with a GeneClamp 500B amplifier (Molecular Devices, In the MM-PBSA approach, the free energy G is given by
Sunnyvale, CA). Voltage-recording and current-injecting electrodes G 5 Egas 1 GPB 1 g 1 b 2 TS, where Egas is the gas-phase molecular
were pulled from borosilicate glass (GC150T-7.5; Harvard Apparatus mechanics potential energy defined by the force field employed, GPB is
Ltd., Holliston, MA) and had resistances of 0.31.5 MV when filled the polar contribution to the solvation free energy calculated using
with 3 M KCl. All recordings were made at room temperature (21 the Poisson-Boltzmann equation, A is the solvent-accessible surface
23C) using a bath solution of ND96 as described above, and oocytes area, g and b are empirical parameters, and TS is the entropy term.
were voltage-clamped at a holding potential of 80 mV. During In the present calculations, the change in entropy is assumed to be
recordings, the oocytes were perfused continuously at a rate of 2 ml/min negligible. The APBS software package was employed for numerical
including application of ACh (50 mM) for 2 seconds and 180240-second solution of the linear Poisson-Boltzmann equation. A grid spacing of
washout periods between applications. Oocytes were incubated with 0.5 was used for the fine cubic lattice. The CHARMM radii and charges
the peptide for 300 seconds before perfusion with ACh plus peptide. were used to generate the PQR files. The continuum medium is assumed
Data were sampled at 500 Hz and filtered at 100 Hz. to have a dielectric constant of 80.00, and the solute was assigned a
Peak ACh-evoked current amplitude was recorded using pClamp 9 dielectric constant of 2. The two empirical parameters were set with g 5
software (Molecular Devices). The effects of peptide on ACh-evoked 0.0226778 kJ/(mol2) and b 5 0. The surface area A was estimated using
currents were defined as peak current amplitudes relative to the a probe radius of 1.4 . The DGbind was decomposed into individual
average peak current amplitude of 35 control ACh applications receptor and toxin residue contributions using g_mmpbsa. For each
recorded before preincubation with the peptides. Concentration-response RegIIA-nAChR complex, DGbind values were calculated for 100 frames
Species Difference of a-Conotoxin RegIIA Potency at nAChRs 995
from each of 10 independent MD simulations. Uncertainties are reported CI 502.9 985.9; nH 5 1.2) at the human a3b2 subtype compared
as S.E.M. over 10 independent simulations and two a3(1)b2(2) with 10.7 nM (95% CI 8.8 12.9; nH 5 1.1) at rat a3b2 subtype
interfaces. Relative binding free energy values [(D)DGbind ] were (Table 1). This change was even more prominent for the
calculated for RegIIA binding to a3[Q198P]b2 and human a3b2, RegIIA analog [N11A,N12A]RegIIA, which was inactive at the
relative to rat a3b2.
ha3b2 subtype at 100 mM while retaining micromolar potency
at ra3b2 (IC50 of 9.9 mM, 95% CI 7.9 12.4 nM; nH 5 1.5) (Fig.
1C). In contrast, [N11A,N12A]RegIIA was almost equipotent
Results at ha3b4 and ra3b4 nAChR subtypes (IC50 of 259.4 nM,
a-Conotoxin RegIIA Exhibits Differential Selectivity 95% CI 224.4 299.9 nM; nH 5 1.8, and 369.6 nM, 95% CI
at the Rat and Human a3b2 but Not a3b4 nAChR 308.9 442.3 nM; nH 5 1.7, respectively) (Fig. 1C).
Subtypes. RegIIA has been shown to selectively inhibit The Nonhomologous Residue Q198 of the Rat a3
ra3b2, ra3b4 and ha7 nAChR subtypes (Franco et al., 2012). Subunit Is a Key Determinant of Species-Specific
To examine if RegIIA exhibits species-specific activity differ- Differences in a-Conotoxin RegIIA Potency at the
ences, inhibition of ACh-evoked currents at human nAChR a3b2 nAChR. To examine possible structural features that
subtypes expressed in Xenopus oocytes was investigated. determine species-specific differences in sensitivity to RegIIA,
Surprisingly, an initial screening with 100 nM RegIIA at rat and human a3 and b2 subunit N-terminal ECD protein
ha3b2 demonstrated only minor (12%) reduction of ACh- sequences were compared. Pairwise alignments of mature

Downloaded from molpharm.aspetjournals.org at ASPET Journals on August 30, 2017


evoked current amplitude, whereas the same concentration protein sequences lacking the signal peptide revealed a
almost completely blocked the homologous rat a3b2 nAChR number of nonconserved residues (Fig. 2, A and B). The ECD of
subtype (Fig. 1A) (Franco et al., 2012). However, at rat and the b2 subunit is highly homologous between the two species,
human a3b4 nAChR subtypes, 100 nM RegIIA exhibited differing in only three amino acid residues (98.6% homology).
similar inhibitory effects on ACh-evoked currents (Fig. 1A). In the rat sequence, these are D73 (E in human), D165 (E in
Concentration-response curves for RegIIA inhibition of ha3b2 human) and I181 (V in human) (Fig. 2B). All three sites
showed a significant shift to the right relative to that of the represent conservative amino acid substitutions. The a3 subunit
homologous rat receptor, whereas RegIIA activity at rat and exhibits eleven nonconserved residues in the ECD of the mature
human a3b4 receptors showed no distinguishable change proteins (Fig. 2A). However, only three nonhomologous residues
(Fig. 1B). IC50 values calculated from the concentration- were identified within the ACh-binding loops that correspond to
response curves revealed an approximately 70-fold differ- the previously identified and homologous loops of the a7 subunit
ence in RegIIA activity with an IC50 of 704.1 nM (95% (Corringer et al., 2000). These are rat a3 E187 (D in human) and

Fig. 1. Inhibition of rat and human a3b2 and a3b4 nAChR


subtypes by a-conotoxin RegIIA. (A) Representative super-
imposed ACh-evoked currents obtained in the absence
(control, solid line) and presence of 100 nM RegIIA (dashed
line) at rat and human a3b2 and a3b4 nAChRs. (B)
Concentration-response curves for RegIIA inhibition of rat
and human a3b2 and a3b4 nAChRs reveal RegIIA is
approximately 70-fold less potent at human compared with
rat a3b2 nAChR. RegIIA is equipotent at a3b4 nAChRs of
both species. The IC50, 95% CI and Hill slope (nH) values
obtained from the concentration-response curves are shown
in Table 1. (C) Concentration-response curves for the synthetic
analog [N11A,N12A]RegIIA show no activity at human a3b2
compared with micromolar potency at the rat homolog. No
species-specific differences in potency were observed at a3b4
nAChR. Data represent mean 6 S.E.M., n = 36.
996 Kompella et al.

TABLE 1 values indicated that, compared with ra3b2, there is moderate


RegIIA inhibition of nAChR subtypes and subtype mutantsa evidence for lower RegIIA binding to ra3[Q198P]b2, and
nAChR/mutant IC50 95% CI nH
statistically significant lower RegIIA binding to ha3b2. These
findings are in qualitative agreement with the experimental
nM nM
ra3b2 10.7b 8.812.9b 1.1b oocyte recording data.
ha3b2 704.1 502.9985.9 1.2 We next aimed to identify the RegIIA and a3b2 residues
ra3b4 47.3b 39.556.6b 1.5b that make the most significant contribution to the loss in
ha3b4 52.1 42.963.3 1.9
RegIIA affinity at a3[Q198P]b2 and human a3b2. We used the
ra3[Q73G]+[V75A]b2 29.6 23.936.7 2.3
ra3[D97V]b2 28.3 23.833.7 1.7 g_mmpbsa script (Kumari et al., 2014) to decompose DGbind
ra3[E187D]b2 7.3 5.010.8 1.7 into individual contributions from RegIIA and nAChR. A
ra3[Q198P]b2 520.9 400.2678.1 0.8 (D)DG bind value for each residue was then calculated by
ha3[P198Q]rb2 31.0 25.038.4 1.8
ra3b2[D73E] 37.6 29.448.1 1.4 subtracting the (per-residue) DGbind of rat a3b2 from those of
ra3b2[D165E] 32.2 26.539.0 1.7 the RegIIA-inactive subtypes. Inspection of (D)DGbind values
ra3b2[I181V] 39.2 31.349.0 1.1 for each RegIIA moiety interacting at a3[Q198P]b2 or ha3b2
a
IC50 values with 95% CI. Hill slope (nH) obtained from concentration-response revealed a number of residues with a significantly positive
curves for RegIIA at wild-type and mutant rat and human a3b2 and a3b4 nAChR (D)DGbind for both RegIIA-inactive a3b2 subtypes (marked
subtypes. Rat a3[Q198P]b2 nAChR notably shifts the IC50 of RegIIA toward the
human a3b2 subtype value. Data from both subtypes are highlighted in bold font. All with asterisks in Fig. 3B, p , 0.05). Of particular interest are

Downloaded from molpharm.aspetjournals.org at ASPET Journals on August 30, 2017


data represent mean of n = 46 experiments.
b
RegIIA-N11 (13.5 6 0.2 kJ/mol at a3[Q198P]b2 and 14.6 6
Data from previous report (Kompella et al., 2015).
0.2 kJ/mol at ha3b2) and RegIIA-N12 (12.2 6 0.2 kJ/mol at
a3[Q198P]b2 and 12.3 6 0.2 kJ/mol at ha3b2). Both N11 and
Q198 (P in human) located within loop C and rat b2 D165 (E in N12 are in close proximity to a3-E195 in loop C (three
human) within loop F. residues away from the key residue a3-Q198). a3-E195 also
To evaluate the contribution of each nonhomologous amino exhibits positive (D)DGbind values for both ra3[Q198P]b2 and
acid to the observed 70-fold difference in RegIIA activity, we ha3b2 (18.8 6 1.0 kJ/mol and 110.0 6 2.0 kJ/mol, re-
carried out site-directed mutagenesis of rat a3 and b2 residues spectively, p , 0.05) (Fig. 4A). Moreover, for both ra3b4 and
to the human counterparts (denoted by boxes in Fig. 2, A and ha3b4, a3-E195 also exhibits positive (D)DGbind relative to
B). When tested for sensitivity to RegIIA, all mutations, except ra3b2; however, they are much lower than for the RegIIA-
for rat a3[Q198P]b2, caused only modest, 3- to 4-fold, changes inactive subtypes discussed above (12.2 6 1.0 and 2.6 6 1.0 kJ/mol,
in IC50 (Fig. 2D, Table 1). In contrast, exchange of the single respectively), and neither are significantly different from that
residue Q198 to P was sufficient to shift the RegIIA concentration- of ra3b2. The statistically significant positive (D)DGbind
response curve 50-fold; from an IC50 of 10.7 nM (95% CI 8.8 12.9; contributions of RegIIA-N11/N12, together with that of a3-E195
nH 5 1.1) in wild-type ra3b2 to an IC50 of 520.9 nM (95% CI for ha3b2 and a3[Q198P]b2, but not for ha3b4 and ra3b4,
400.2 678.1; nH 5 0.8) in ra3[Q198P]b2. The latter value was suggests the interactions between these residues play a key
similar to the IC50 obtained with ha3b2 (Fig. 2C, Table 1). The role in differentiating RegIIA activity at the RegIIA-active rat
opposite human a3 receptor subunit mutant ha3[P198Q]b2, a3b2 and a3b4 subtypes compared with the two RegIIA-
expressed in oocytes, exhibited substantially reduced sensi- inactive receptors in this study.
tivity to ACh compared with the wild-type (.1000-fold), and Additionally, we identified that b2-S168 at the complemen-
therefore the activity of RegIIA could not be evaluated. tary face exhibits marginally positive, though statisti-
However, when ha3[P198Q] was coexpressed with rat b2, the cally significant, (D)DGbind values for both ra3[Q198P]b2 (11.0 6
hybrid ha3[P198Q]rb2 receptor produced robust ACh-evoked 0.2 kJ/mol) and ha3b2 (12.0 6 0.2 kJ/mol) (p , 0.05) (Fig. 4D).
currents. The concentration-response curve for inhibition of At all a3b2 receptors studied, b2-S168 is in occasional contact
ha3[P198Q]rb2 by RegIIA was shifted to the left compared with with RegIIA-S4. We note that S4 also exhibits statistically
ha3b2, exhibiting an IC50 concentration of 31.0 nM (95% CI significant positive (D)DGbind values at ra3[Q198P]b2 and
25.0 38.4; nH 5 1.8) (Fig. 2C, Table 1). Taken together these ha3b2 (12.2 6 0.2 and 13.5 6 0.2 kJ/mol, respectively, p ,
findings revealed P198 in human a3 as a critical determinant 0.05). This may be partly attributable to the marginally more
for the reduced potency of RegIIA at ha3b2 compared with the stable H-bond between S4 and b2-S168 at ra3b2 (not shown).
homologous rat nAChR subtype. Interestingly, for ra3b2, b2-S168 forms a hydrogen bond with
MD Simulations and Free Energy Calculations Re- neighboring b2-D171. This, in turn, forms a persistent salt bridge
veal the Molecular Mechanisms by Which Human a3 with the N-terminal amine of RegIIA-G1. Inspection of the
P198 Governs Loss of Sensitivity to a-Conotoxin (D)DGbind values for RegIIA (Fig. 3B) reveals a significant
RegIIA. We performed all-atom MD simulations of the ECDs of (D)DGbind contribution by RegIIA-G1 at ha3b2 (13.9 6 0.6 kJ/mol,
rat wild-type, rat a3[Q198P]b2 and human a3b2 receptors p , 0.05). However, there was no significant (D)DGbind contri-
complexed with RegIIA. To understand the molecular basis for bution at a3[Q198P]b2 (p 1.0). These results suggest both
lack of low-nanomolar inhibition at ra3[Q198]b2 and ha3b2 principal and complementary subunits contribute to species
receptors by RegIIA (hereafter termed RegIIA-inactive sub- differences in RegIIA activity at human and rat a3b2. However,
types), we employed MM-PBSA calculations on the MD simulation it is mainly the principal face that confers selectivity between
trajectories to estimate the absolute DGbind of RegIIA to each of wild-type ra3b2 and ra3[Q198P]b2.
the receptors. These values were then used to estimate the
(D)DGbind of RegIIA to a3[Q198P]b2 and human a3b2, relative
to rat a3b2 (Fig. 3A). Both ra3[Q198P]b2 and ha3b2 exhibited
Discussion
positive (D)DGbind values of 15.0 6 2.5 kJ/mol (p 5 0.07) and 1 a-Conotoxins are valuable pharmacological tools for study-
9.3 6 2.5 kJ/mol (p , 0.05), respectively. These calculated ing nAChR function because they exhibit different specificities
Species Difference of a-Conotoxin RegIIA Potency at nAChRs 997

Downloaded from molpharm.aspetjournals.org at ASPET Journals on August 30, 2017


Fig. 2. The nonhomologous residue at position 198 (Q in rat, P in human) of the a3 subunit is responsible for the species differences in potency of
a-conotoxin RegIIA. (A, B) Sequence alignments of the N-terminal ECDs of rat and human a3 nAChR subunits (A) and b2 nAChR subunits (B) reveal
species-specific differences in amino acid sequences. Residues that differ between the two species are highlighted in bold and conserved residues are
indicated with dots. Residues that were mutated for testing in this study are framed. Bars indicate the ACh binding domain loops A, B, and C of the
principal interface, and loops D, E, and F of the complementary interface, respectively (see Shiembob et al., 2006). (C) Concentration-response curves for
RegIIA inhibition of the rat a3[Q198P]b2 mutant (red) and ha3[Q198P]rb2 hybrid mutant (blue) compared with rat and human a3b2. (D) Bar graph of
IC50 values obtained from concentration-response curves for RegIIA inhibition of rat, human and mutant a3b2 nAChRs. Compared with wild-type rat
a3b2 nAChR, human wild-type and mutant rat a3[Q198P]b2 show significant changes in IC50 values. The b2 subunit makes only minor contributions to
the difference in potency of RegIIA. IC50, 95% CI and Hill slope (nH) values are shown in Table 1. All data points represent mean 6 S.E.M., n = 36, ***p ,
0.001.

for different receptor subtypes (Terlau and Olivera, 2004; pharmacology and to the development of new, selective and
Muttenthaler et al., 2011; Lebbe et al., 2014). They are also potent pharmacological probes.
promising lead compounds for drugs that target pathophysi- Evidence that a-conotoxins can exhibit considerably differ-
ological conditions related to nAChRs, such as chronic pain, ent potencies on homologous nAChR subtypes of different
cancers, and addiction (Olivera et al., 2008; Brady et al., 2013; species comes from a few recent reports (Azam and McIntosh,
Schroeder et al., 2013). However, most a-conotoxins have only 2012; Yu et al., 2013; Azam et al., 2015). Here, we report novel
been characterized at heterologously expressed receptors in one species- and receptor subtype-specific differences between
species, usually rat, in expression systems such as Xenopus a3b2 and a3b4 nAChR sensitivity to a-conotoxin RegIIA.
oocytes. Evaluating a-conotoxin activity at human nAChR RegIIA, previously characterized as a competitive antagonist
subtypes is crucial for our understanding of human nAChR of rat a3b2 nAChR with an IC50 of 10.7 nM (Kompella et al.,
998 Kompella et al.

when any of the three nonhomologous residues in the rat b2


subunit are exchanged to the human counterpart, only modest loss
in sensitivity to RegIIA is observed (Fig. 2D). Conversely, a single
exchange of residue Q198 in loop C of the rat a3 subunit can shift
the IC50 to values consistent with those of human a3b2 nAChRs
(Fig. 2, C and D).
Other mutations around loop A ([Q73G,V75A] and [D97V])
and loop C ([E187D]) in the rat a3 subunit do not cause any
significant loss in activity (Fig. 2D and Table 1). Taken together
the mutational analyses show that only a single residue in the
ECD of the a3 subunit, located within the principal interface
of the ACh binding domain, appears crucial for the 70-fold
RegIIA potency differences at human and rat a3b2.
Interestingly, a-conotoxin RgIAs affinity for the rat a9a10
nAChR was previously reported to be about 100-fold higher
than that for the human subtype. Similarly to our findings
with RegIIA and a3b2, only a single residue difference in the

Downloaded from molpharm.aspetjournals.org at ASPET Journals on August 30, 2017


a9 subunit (Thr56 to Ile) was responsible for this two orders of
magnitude change in affinity, as shown by receptor mutagen-
esis (Azam and McIntosh, 2012).
To understand the role of Q198P exchange in RegIIA species
selectivity, we dissected the contribution of individual nAChR
residues to RegIIA binding. MM-PBSA free-energy calcula-
tions reveal the importance of a3(1)-E195 (Fig. 4A), which
does not interact with RegIIA in ra3b2 (Fig. 4B) but does interact
with RegIIA-N11 and N12 for ha3b2 and ra3[Q198P]b2 (illus-
trated for ha3b2 in Fig. 4C). We propose that, for a3[Q198P]b2
and ha3b2, the stronger interaction of a3-E195 with RegIIA-
N12 causes steric hindrance, displacing RegIIA-N12 from its key
contact with a3-Y197, the latter contact being present only in
ra3b2 (Fig. 4B). This leads to energetically less favorable peptide
binding.
MM-PBSA calculations also revealed that for rat and human
a3b4 subtypes, at which RegIIA is active, the contribution of
a3(1)-E195 to (D)DGbind is not significantly different from that of
ra3b2 (unlike ha3b2 and ra3[Q198P]b2). This further supports
the notion that a3(1)-E195 is key to species-specific RegIIA
inhibition. Therefore, although the a3 subunit is common be-
tween a3b2 and a3b4 subtypes, the complementary b subunit
may help to change RegIIAs interactions with the a3 subunit,
leading to species-dependent inhibition at a3b2 but not a3b4.
Fig. 3. MM-PBSA calculations were performed on the MD simula-
tion trajectories to estimate the absolute free binding energy (DGbind) Interestingly, the reverse mutation at the homologous position
of RegIIA to each of the receptors. (A) Bar graph summarizing the in rat a4, P195Q, enhances a-conotoxin TxIA potency at a4b2.
binding free energy relative to rat a3b2 [(D)DGbind] between RegIIA and MD simulations of TxIA bound with an a4b2 dimer showed
rat a3[Q198P]b2 and human a3b2. Positive (D)DGbind values for ra3[Q198]b2
and ha3b2 receptors indicate RegIIA binds to these receptors with lower
that P195 does not directly face the peptide binding site, but
affinity than to ra3b2 (*p , 0.05). (B) (D)DGbind values between RegIIA and structurally changes loop C and prevents nearby residues from
human a3b2 (open bars) and rat a3[Q198P]b2 (filled bars) were decomposed interacting with the peptide. Mutation a4[P195Q] improves
to the individual amino acid level to analyze contributions from each of the flexibility of loop C, which increases the number of contacts
16 RegIIA residues. Residues S4, N11, and N12 exhibit significantly positive
(D)DGbind values (*p , 0.05). RegIIA-G1 is the only RegIIA residue making between loop C residues (including a4-Y194) and TxIA (Beissner
substantial contact with b2(2) and exhibiting a positive (D)DGbind, but it is not et al., 2012). Surprisingly, we observed a severe loss in the
statistically significant (+p = 0.17). affinity of the human a3b2 nAChR mutant ha3[P198Q]b2 for
ACh. However, when coexpressed with rat b2 instead, as in the
above paper, the hybrid ha3[P198Q]rb2 receptor produced
2015), is 70-fold less potent at the homologous human a3b2 robust ACh-evoked currents and revealed a left-shift of the
subtype (IC50 of 704 nM). Interestingly, human and rat a3b4 concentration-response curve of RegIIA. This confirmed how
nAChR subtypes have the same sensitivity to RegIIA. important residue a3-Q198 is for determining receptor affinity
The potency difference observed at a3b2 but not a3b4 for RegIIA.
subtypes suggests that only a few critical structural components The results reported by Beissner and coworkers (2012) are
at the a3b2 ACh binding pocket are responsible. Since RegIIA consistent with our proposed mechanism, in which contact
exhibits no change in activity at the a3b4 subtype, we antici- between a3-Y197 (homologous to a4-Y194) and the residues
pated that residue differences in the b2 subunit caused the RegIIA-N11 and -N12 plays a key role in the potency of RegIIA
70-fold lower sensitivity at the human a3b2 subtype. Surprisingly, at ra3b2.
Species Difference of a-Conotoxin RegIIA Potency at nAChRs 999

Fig. 4. MD simulations reveal key residues on


a3b2 nAChRs and RegIIA for species-specific
difference in sensitivity to the peptide. (A) Bar
graph summarizing (D)DGbind between RegIIA and
residue a3-E195 of human a3b2 and mutant
ra3[Q198]b2 relative to rat a3b2. In the a3(+)
subunit, a3-E195 exhibits a significantly more
positive (D)DGbind at ra3[Q198]b2 and ha3b2
receptors (*p , 0.05). (B) Graphical representation
of rat a3-E195 interaction with RegIIA. Rat a3
nAChR backbone is depicted in transparent blue
ribbon form with residues of interest either as
space-filling (ra3-Q198) or licorice models (ra3-E195,
ra3Y197). The a-conotoxin RegIIA backbone is
shown in a yellow ribbon representation and
residues N11 and N12 highlighted in licorice form.
Dashed lines indicate approximate distances be-

Downloaded from molpharm.aspetjournals.org at ASPET Journals on August 30, 2017


tween receptor and toxin side-chain atoms of in-
terest. Atoms are color coded as: C, cyan; H, white;
N, blue; and O, red. MD analysis reveals that at the
a3(+) subunit in rat a3b2, RegIIA-N12 forms a
H-bond with a3-Y197, whereas a3-E195 has less
effect on peptide binding due to greater distance. (C)
At human a3b2, the H-bond between a3-Y197 and
RegIIA-N12 is disrupted and replaced by a H-bond
between N12 and a3-E195. In addition, residue
a3-E195 makes close contact with RegIIA-N11 po-
tentially forming another H-bond. (D) Bar graph
summarizing (D)DG bind between RegIIA and
residue b2-S168. On the b2(2) subunit of human
a3b2 and mutant ra3[Q198]b2 receptors, resi-
due b2-S168 exhibits significantly increased
(D)DGbind for RegIIA (*p , 0.05). (E) Graphical
representation of rat b2-S168 interaction with
RegIIA. Rat b2 nAChR backbone is depicted in
transparent red ribbon form. RegIIA-G1 (N-terminal
amine) forms a salt bridge with b2-D171, which in
turn forms a H-bond with b2-S168. (F) Both interac-
tions are absent with human a3b2. Error bars in (A)
and (D) are calculated as S.E.M. over 10 independent
simulations and two a3(+)b2(2) interfaces.

At b2(2), S168 makes the most statistically significant locks Y197 into a specific conformation that may partly confer
positive (D)DGbind contribution to a3[Q198P]b2 and ha3b2 favorable binding of ra3b2 with RegIIA, compared with the
(Fig. 4D). In ra3b2, b2-S168 does not form any close contact two RegIIA-inactive receptors.
with RegIIA but does form an intrasubunit hydrogen bond Similarly for ra3b2, at b2(2), the distance between the
with b2-D171. In turn, this forms a persistent salt bridge with hydroxyl H of S168 and side-chain C of D171 lies within 3.5
the RegIIA-G1 N-terminus (Fig. 4E). In contrast, at a3[Q198P]b2 for 50% of the time (shaded areas in Fig. 5, D and E). In
and human a3b2, both interactions are absent (Fig. 4F). We contrast, for ra3[Q198]b2 and ha3b2, the contact time is 9%
propose that, by stabilizing b2-D171 in a conformation that and 5%, respectively, indicating lack of a persistent contact (Fig.
allows salt bridge contact with RegIIA-G1, the internal H-bond 5, D and F). This trend is also present when RegIIA is bound (Fig.
between b2-S168 and b2-D171 plays an indirect role in facili- 4, DF). A persistent contact between S168 and D171 for RegIIA-
tating RegIIA activity at ra3b2. bound and apo ra3b2 supports how important this interaction is,
MD simulations also reveal differences between the three in particular for maintenance of D171 in a position potentially
receptors in the absence of RegIIA that may help to bias ra3b2 enabling salt bridge formation with the N terminus of RegIIA.
toward favorable binding with RegIIA. At ra3(1), in approx- We used MD simulation and alanine-scanning analysis to
imately 80% of the MD trajectories, the distance between the identify interactions between residue a3-Q198 and a-conotoxin
hydroxyl H of Y197 and side-chain Cd of E195 lies within 3.5 AuIB at the rat a3b4 nAChR subtype (Grishin et al., 2013).
(shaded areas in Fig. 5A), suggesting the existence of a However, at a3b4, this residue is not the major determinant for
persistent contact (Fig. 5B). For ra3[Q198P](1), this contact AuIB potency. The main determinants for AuIB potency are on
exists only 40% of the time (Fig. 5, A and C), whereas the the b4 subunit (Grishin et al., 2013). These findings indicate the
ha3(1) lies inbetween at 70% (Fig. 5A). This interaction a3 residue at position 198 does not appear to have the same
1000 Kompella et al.

Fig. 5. MD simulations on apo a3b2 nAChRs


exhibit intrinsic structural differences that may
bias human and rat [Q198P]b2 receptors toward
lower RegIIA sensitivity. (A) Histogram of inter-
atomic distance between the side-chain polar
hydrogen (OH) of a3-Y197 and side-chain Cd of
a3-E195 from MD simulations of apo ra3b2 (black),
ra3[Q198P]b2 (orange), and ha3b2 (green). The
relative frequency of any inter-atomic distance
appearing in the simulation is plotted as a percent-
age value. Shaded areas indicate the total percent-
age frequency of indicated inter-atomic contacts is
within a distance of #3.5 . (B) Graphical repre-
sentation of the a3(+)b2(2) interface of apo ra3b2
with a3 in blue and b2 in red ribbon form. Residues

Downloaded from molpharm.aspetjournals.org at ASPET Journals on August 30, 2017


a3-E195 and a3-Y197 are highlighted in licorice
representation and a3-Q198 as a space-filling
model. The dashed line represents the distance
between the atoms analyzed. Persistent internal
H-bonds exist between a3-Y197 and a3-E195 for
apo ra3b2, locking Y197 in a conformation suitable
for (potential) H-bonding with RegIIA-N11/N12. (C)
This H-bond is less persistent for apo ra3[Q198P]b2
(and ha3b2, not shown), leading to greater variation in
Y197 OH bond rotation. (D) Histogram of inter-atomic
distance between the side-chain polar hydrogen
(OH) of b2-S167 and side-chain C of b2-D171 from
apo ra3b2 (black), ra3[Q198P]b2 (orange) and
ha3b2 (green). (E) Persistent internal H-bonds
exist between b2-S167 and D171 for apo ra3b2,
locking D171 in a conformation suitable for (poten-
tial) H-bonding with the RegIIA N-terminus. (F)
Lack of the latter H-bond for apo ra3[Q198P]b2
(and ha3b2, not shown) results in greater flexibility
in D171.

importance for binding a-conotoxins in a3b4 as it has in a3b2. potencies of species-specific nAChR antagonists will facilitate
Our experimental data with RegIIA, which lacks a major the design and development of novel, potent and highly
species-specific difference in sensitivity at a3b4, support this subtype-selective nAChR drugs. An in-depth understanding
hypothesis. Furthermore, MD simulations indicate that, simi- of the structural prerequisites for human nAChR-selective
lar to AuIB, other residues specific for b4 within the agonist probes will also increase the success rates of drug candidates
binding loops are more important for determining RegIIAs in clinical trials.
binding affinity for a3b4.
Recent studies of the molecular and structural basis for Authorship Contributions
a-conotoxin BuIA and LvIA selectivity identified key residues Participated in research design: Adams, Kompella, Cuny, Hung.
on the b(2) interface of the b2 subunit that contribute to these Conducted experiments: Kompella, Cuny, Hung.
toxins activity and selectivity (Shiembob et al., 2006; Zhangsun Contributed new reagents or analytic tools: Adams.
et al., 2015), confirming that each a-conotoxin requires specific Performed data analysis: Cuny, Kompella, Hung, Adams.
Wrote or contributed to the writing of the manuscript: Kompella,
structural determinants for effective receptor binding.
Cuny, Hung, Adams.
Our study provides novel pharmacological information
about conformational differences at the a(1) interface of rat References
and human a3b2 subtypes, and how these differences affect Azam L and McIntosh JM (2012) Molecular basis for the differential sensitivity of rat and
activity of the competitive antagonist RegIIA. Furthermore, human a9a10 nAChRs to a-conotoxin RgIA. J Neurochem 122:11371144.
Azam L, Papakyriakou A, Zouridakis M, Giastas P, Tzartos SJ, and McIntosh JM
the synthetic peptide [N11A,N12A]RegIIA is, to our knowl- (2015) Molecular interaction of a-conotoxin RgIA with the rat a9a10 nicotinic
edge, the most selective pharmacological probe available that acetylcholine receptor. Mol Pharmacol 87:855864.
Beissner M, Dutertre S, Schemm R, Danker T, Sporning A, Grubmller H, and Nicke
selectively inhibits the human a3b4 nAChR over the a3b2 A (2012) Efficient binding of 4/7 a-conotoxins to nicotinic a4b2 receptors is pre-
subtype. Identifying the molecular basis for the different vented by Arg185 and Pro195 in the a4 subunit. Mol Pharmacol 82:711718.
Species Difference of a-Conotoxin RegIIA Potency at nAChRs 1001
Bjelkmar P, Larsson P, Cuendet MA, Hess B, and Lindahl E (2010) Implementation Kompella SN, Hung A, Clark RJ, Mar F, and Adams DJ (2015) Alanine scan of
of the CHARMM force field in GROMACS: Analysis of protein stability effects from a-conotoxin RegIIA reveals a selective a3b4 nicotinic acetylcholine receptor an-
correction maps, virtual interaction sites, and water models. J Chem Theory tagonist. J Biol Chem 290:10391048.
Comput 6:459466. Kumari R, Kumar R, and Lynn A; Open Source Drug Discovery Consortium (2014)
Brady RM, Baell JB, and Norton RS (2013) Strategies for the development of con- g_mmpbsaa GROMACS tool for high-throughput MM-PBSA calculations. J Chem
otoxins as new therapeutic leads. Mar Drugs 11:22932313. Inf Model 54:19511962.
Bussi G, Donadio D, and Parrinello M (2007) Canonical sampling through velocity Lebbe EK, Peigneur S, Wijesekara I, and Tytgat J (2014) Conotoxins targeting nic-
rescaling. J Chem Phys 126:014101. otinic acetylcholine receptors: an overview. Mar Drugs 12:29703004.
Celie PH, Kasheverov IE, Mordvintsev DY, Hogg RC, van Nierop P, van Elk R, van Lindahl E, Hess B, and van der Spoel D (2001) GROMACS 3.0: A package for mo-
Rossum-Fikkert SE, Zhmak MN, Bertrand D, and Tsetlin V et al. (2005) Crystal lecular simulation and trajectory analysis. J Mol Model 7:306317.
structure of nicotinic acetylcholine receptor homolog AChBP in complex with an Millar NS and Gotti C (2009) Diversity of vertebrate nicotinic acetylcholine receptors.
a-conotoxin PnIA variant. Nat Struct Mol Biol 12:582588. Neuropharmacology 56:237246.
Corringer PJ, Le Novre N, and Changeux JP (2000) Nicotinic receptors at the amino Muttenthaler M, Akondi KB, and Alewood PF (2011) Structure-activity studies on
acid level. Annu Rev Pharmacol Toxicol 40:431458. a-conotoxins. Curr Pharm Des 17:42264241.
Decker MW, Gopalakrishnan M, and Meyer MD (2008) The potential of neuronal Olivera BM, Quik M, Vincler M, and McIntosh JM (2008) Subtype-selective con-
nicotinic acetylcholine receptor agonists for treating CNS conditions. Expert Opin opeptides targeted to nicotinic receptors: Concerted discovery and biomedical ap-
Drug Discov 3:10271040. plications. Channels (Austin) 2:143152.
Dolinsky TJ, Nielsen JE, McCammon JA, and Baker NA (2004) PDB2PQR: an au- Parrinello M and Rahman A (1981) Polymorphic transitions in single-crystals a
tomated pipeline for the setup of Poisson-Boltzmann electrostatics calculations. new molecular-dynamics method. J Appl Phys 52:71827190.
Nucleic Acids Res 32(Web Server issue):W665667. Sali A and Blundell TL (1993) Comparative protein modelling by satisfaction of
Dolinsky TJ, Czodrowski P, Li H, Nielsen JE, Jensen JH, Klebe G, and Baker NA spatial restraints. J Mol Biol 234:779815.
(2007) PDB2PQR: expanding and upgrading automated preparation of bio- Schroeder CI, Swedberg JE, and Craik DJ (2013) Recent progress towards phar-
molecular structures for molecular simulations. Nucleic Acids Res 35(Web Server maceutical applications of disulfide-rich cyclic peptides. Curr Protein Pept Sci 14:
issue):W522525. 532542.
Franco A, Kompella SN, Akondi KB, Melaun C, Daly NL, Luetje CW, Alewood PF, Shiembob DL, Roberts RL, Luetje CW, and McIntosh JM (2006) Determinants of

Downloaded from molpharm.aspetjournals.org at ASPET Journals on August 30, 2017


Craik DJ, Adams DJ, and Mar F (2012) RegIIA: an a4/7-conotoxin from the venom of a-conotoxin BuIA selectivity on the nicotinic acetylcholine receptor b subunit.
Conus regius that potently blocks a3b4 nAChRs. Biochem Pharmacol 83:419426. Biochemistry 45:1120011207.
Grishin AA, Cuny H, Hung A, Clark RJ, Brust A, Akondi K, Alewood PF, Craik DJ, Terlau H and Olivera BM (2004) Conus venoms: a rich source of novel ion channel-
and Adams DJ (2013) Identifying key amino acid residues that affect a-conotoxin targeted peptides. Physiol Rev 84:4168.
AuIB inhibition of a3b4 nicotinic acetylcholine receptors. J Biol Chem 288: Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, and Berendsen
3442834442. HJ (2005) GROMACS: fast, flexible, and free. J Comput Chem 26:
Hansen SB, Sulzenbacher G, Huxford T, Marchot P, Taylor P, and Bourne Y (2005) 17011718.
Structures of Aplysia AChBP complexes with nicotinic agonists and antagonists Yu R, Kompella SN, Adams DJ, Craik DJ, and Kaas Q (2013) Determination of the
reveal distinctive binding interfaces and conformations. EMBO J 24:36353646. a-conotoxin Vc1.1 binding site on the a9a10 nicotinic acetylcholine receptor. J Med
Hogg RC, Hopping G, Alewood PF, Adams DJ, and Bertrand D (2003) a-conotoxins Chem 56:35573567.
PnIA and [A10L]PnIA stabilize different states of the a7-L247T nicotinic acetyl- Zhangsun D, Zhu X, Wu Y, Hu Y, Kaas Q, Craik DJ, McIntosh JM, and Luo S (2015)
choline receptor. J Biol Chem 278:2690826914. Key residues in the nicotinic acetylcholine receptor b2 subunit contribute to
Humphrey W, Dalke A, and Schulten K (1996) VMD: visual molecular dynamics. a-conotoxin LvIA binding. J Biol Chem 290:98559862.
J Mol Graph 14:3338, 2728.
Hurst R, Rollema H, and Bertrand D (2013) Nicotinic acetylcholine receptors: from
basic science to therapeutics. Pharmacol Ther 137:2254. Address correspondence to: Dr. David J. Adams, Health Innovations
Jensen AA, Frlund B, Liljefors T, and Krogsgaard-Larsen P (2005) Neuronal nico- Research Institute, RMIT University, PO Box 71, Bundoora, Victoria 3083,
tinic acetylcholine receptors: structural revelations, target identifications, and Australia. E-mail: david.adams@rmit.edu.au
therapeutic inspirations. J Med Chem 48:47054745.

You might also like